nach oben

Erschienen in:

20.12.2022 | COVID-19 | Im - Original

Serological response to COVID-19 pneumonia and increasing severity over 18 months in a prospective cohort of hospitalized patients

verfasst von: Gemma Grau Gómez, Xavier Martínez Lacasa, Roser Costa, Bienvenido Barreiro, Miguel Leal, Emma Padilla, Pepa Pérez, Marc Garreta, Judith Vidal, Angeles Jaen, Helena Monzón Camps, COMUTE Study Group (COVID-19 Mutua Terrassa Study Group)

Erschienen in: Internal and Emergency Medicine | Ausgabe 2/2023

Einloggen, um Zugang zu erhalten

Abstract

In this study, we present an 18-month serological follow-up of 294 patients with COVID-19 pneumonia. The aim was to assess the dynamics of serological response and its correlation with clinical worsening, as well as to describe clinical worsening determinants. Results of the study showed an early immunoglobulin M response, which clearly diminished starting at 4 months, but nonetheless, a small group of patients remained positive. As for immunoglobulin G, levels were higher up to 6 months in patients who presented clinical worsening during hospitalization. High titers of the immunoglobulin were maintained in all patients during follow-up, which would indicate that humoral immunity due to infection is long-lasting. Male sex, presence of myalgias and extensive radiological affectation were significantly correlated with clinical worsening.

Louie JK, Hacker JK, Mark J et al (2004) SARS and common viral infections. Emerging Infect Dis 10:1143–1146. https://doi.org/10.3201/eid1006.030863CrossRef

Peeling RW, Heymann DL, Teo YY et al (2022) Diagnostics for COVID-19: moving from pandemic response to control. Lancet 399:757–768. https://doi.org/10.1016/S0140-6736(21)02346-1CrossRefPubMed

Fang Y, Zhang H, Xie J et al (2020) Sensitivity of chest CT for COVID-19: comparison to RT-PCR. Radiology 296:115–117. https://doi.org/10.1148/radiol.2020200432CrossRef

Ai T, Yang Z, Hou H et al (2020) Correlation of chest CT and RT-PCR testing for coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases. Radiology 296:32–40. https://doi.org/10.1148/radiol.2020200642CrossRef

Burrell CJ, Howard CR, Murphy FA (2017) Laboratory diagnosis of virus diseases. Fenner and White’s Med Virol 1:135–154. https://doi.org/10.1016/B978-0-12-375156-0.00010-2CrossRef

Castro X, Ols S, Karin L et al (2022) Immunity to SARS-CoV-2 induced by infection or vaccination. J Inter Med 291(1):32–50. https://doi.org/10.1111/joim.13372CrossRef

Huang C (2021) Pathogenesis of coronaviruses through human monocytes and tissue macrophages. Viral Immunol 34(9):597–606. https://doi.org/10.1089/vim.2021.0038CrossRefPubMed

Arabi YM, Hajeer AH, Balkhy H et al (2021) Kinetics of antibody response in critically ill patients with Middle East respiratory syndrome and association with mortality and viral clearance. Sci Rep 11(1):22548. https://doi.org/10.1038/s41598-021-01083-yCrossRefPubMedPubMedCentral

García-Abellán J, Padilla S, Fernández-González M et al (2021) Antibody response to SARS-CoV-2 is associated with long-term clinical outcome in patients with COVID-19: a longitudinal study. J Clin Immunol 41(7):1490–1501. https://doi.org/10.1007/s10875-021-01083-7CrossRefPubMedPubMedCentral

10.

Shang Y, Liu T, Li J et al (2021) Factors affecting antibody response to SARS-CoV-2 in patients with severe COVID-19. J Med Virol 93(2):612–614. https://doi.org/10.1002/jmv.26379CrossRefPubMed

11.

Han Y, Liu P, Qiu Y (2021) Effective virus-neutralizing activities in antisera from the first wave of survivors of severe COVID-19. JCI Insight 6(4):e146267. https://doi.org/10.1172/jci.insight.146267CrossRefPubMedPubMedCentral

12.

Lee YL, Liao CH, Liu PY et al (2020) Dynamics of anti-SARS-Cov-2 IgM and IgG antibodies among COVID-19 patients. J Infect 81(2):e55–e58. https://doi.org/10.1016/j.jinf.2020.04.019CrossRefPubMedPubMedCentral

13.

Legros V, Denolly S, Vogrig M (2021) A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity. Cell Mol Immunol 18:318–327. https://doi.org/10.1038/s41423-020-00588-2CrossRefPubMed

14.

Jeewandara C, Jayathilaka D, Gomes L et al (2021) SARS-CoV-2 neutralizing antibodies in patients with varying severity of acute COVID-19 illness. Sci Rep 11:2062. https://doi.org/10.1038/s41598-021-81629-2CrossRefPubMedPubMedCentral

15.

Varona JF, Madurga R, Penalver F et al (2021) kinetics of anti-SARS-CoV-2 antibodies over time. Results of 10 month follow up in over 300 seropositive health care workers. Eur J Intern Med 89:97–103. https://doi.org/10.1016/j.ejim.2021.05.028CrossRefPubMedPubMedCentral

16.

Hellerstein M (2020) What are the roles of antibodies versus a durable, high quality T cell response in protective immunity against SARS-CoV-2? Vaccine X 6:100076. https://doi.org/10.1016/j.jvacx.2020.100076CrossRefPubMedPubMedCentral

17.

Lumley SF, Wei J, O’Donnell D et al (2021) The duration, dynamics and determinants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody responses in individual healthcare workers. Clin Infect Dis 73(3):e699–e709. https://doi.org/10.1093/cid/ciab004CrossRefPubMedPubMedCentral

18.

Anichini G, Gandolfo C, Terrosi C et al (2021) Antibody response to SARS-CoV-2 in infected patients with different clinical outcome. J Med Virol 93(4):2548–2552. https://doi.org/10.1002/jmv.26789CrossRefPubMedPubMedCentral

19.

Lagunas-Rangel FA, Chávez-Valencia V (2021) What do we know about the antibody responses to SARS-CoV-2? Immunobiology 226(2):152054. https://doi.org/10.1016/j.imbio.2021.152054CrossRefPubMedPubMedCentral

20.

Chvatal-Medina M, Mendez-Cortina Y, Patiño PJ et al (2021) Antibody responses in COVID-19: a review. Front Immunol 12:633184. https://doi.org/10.3389/fimmu.2021.633184CrossRefPubMedPubMedCentral

21.

Tea F, Ospina Stella A, Aggarwal A et al (2021) SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants. PLoS Med 18(7):e1003656. https://doi.org/10.1371/journal.pmed.1003656CrossRefPubMedPubMedCentral

22.

Plebani M, Padoan A, Negrini D et al (2020) Diagnostic performances and thresholds: the key to harmonization in serological SARS-CoV-2 assays? Clin Chim Acta 509:1–7. https://doi.org/10.1016/j.cca.2020.05.050CrossRefPubMedPubMedCentral

23.

Bonelli F, Sarasini A, Zierold C et al (2020) Clinical and analytical performance of an automated serological test that identifies S1/S2-neutralizing IgG in COVID-19 patients semi quantitatively. J Clin Microbiol 58(9):e01224-e1320. https://doi.org/10.1128/JCM.01224-20CrossRefPubMedPubMedCentral

24.

Yun J, Yang JS, Young S et al (2022) Duration of humoral immunity and cross-neutralizing activity against the alpha, beta, and delta variants after wild-type severe acute respiratory syndrome coronavirus 2 infection: a prospective cohort study. J Infect Dis. https://doi.org/10.1093/infdis/jiac050CrossRef

25.

Shi D, Weng T, Wu J et al (2021) Dynamic characteristic analysis of antibodies in patients with COVID-19: a 13-month study. Front Immunol 12:708184. https://doi.org/10.3389/fimmu.2021.708184CrossRefPubMedPubMedCentral

26.

Sundararaj SJ, Nandini S, Akihide R (2020) Interpreting diagnostic tests for SARS-CoV-2. JAMA 323(22):2249–2251. https://doi.org/10.1001/jama.2020.8259CrossRef

27.

Evans AS, Niederman JC, Cenabre LC et al (1975) A prospective evaluation of heterophile and Epstein-Barr virus-specific IgM antibody tests in clinical and subclinical infectious mononucleosis: specificity and sensitivity of the tests and persistence of antibody. J Infect Dis 132:546–554. https://doi.org/10.1093/infdis/132.5.546CrossRefPubMed

28.

Torii Y, Yoshida S, Yanase Y et al (2019) Serological screening of immunoglobulin M and immunoglobulin G during pregnancy for predicting congenital cytomegalovirus infection. BMC Pregnancy Childbirth 19:205. https://doi.org/10.1186/s12884-019-2360-1CrossRefPubMedPubMedCentral

29.

Ferrari D, Di Resta C, Tomaiuolo R et al (2021) Long-term antibody persistence and exceptional vaccination response on previously SARS-CoV-2 infected subjects. Vaccine 39(31):4256–4260. https://doi.org/10.1016/j.vaccine.2021.06.020CrossRefPubMedPubMedCentral

30.

Sreenath K, Batra P, Vinayaraj EV et al (2021) Coinfections with other respiratory pathogens among patients with COVID-19. ASM J 9(1):ee00163-ee221. https://doi.org/10.1128/Spectrum.00163-21CrossRef

31.

Fei G, Meng W, Chen L et al (2022) Neutralizing antibodies to SARS-CoV-2 variants of concern including Delta and Omicron in subjects receiving mRNA-1273, BNT162b2, and Ad26.COV2.S vaccines. J Med Virol 94:5678–5690. https://doi.org/10.1002/jmv.28032CrossRef

Titel: Serological response to COVID-19 pneumonia and increasing severity over 18 months in a prospective cohort of hospitalized patients
verfasst von: Gemma Grau Gómez
Xavier Martínez Lacasa
Roser Costa
Bienvenido Barreiro
Miguel Leal
Emma Padilla
Pepa Pérez
Marc Garreta
Judith Vidal
Angeles Jaen
Helena Monzón Camps
COMUTE Study Group (COVID-19 Mutua Terrassa Study Group)
Publikationsdatum: 20.12.2022
Verlag: Springer International Publishing
Schlagwort: COVID-19
Erschienen in: Internal and Emergency Medicine / Ausgabe 2/2023
Print ISSN: 1828-0447
Elektronische ISSN: 1970-9366
DOI: https://doi.org/10.1007/s11739-022-03177-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2023

The United Kingdom’s National Early Warning Score: should everyone use it? A narrative review

Burden of firearm-related injuries as associated secondary diagnosis in the United States from National Inpatient Sample Dataset

A reduced glycine-to-taurine ratio of conjugated serum bile acids signifies an adaptive mechanism and is an early marker of outcome in acute respiratory distress syndrome

The role of general practitioners in the EU: time to draw lessons from a too wide range?

Hospital mortality and failure of non-invasive ventilation in COVID-19: looking inside the predictive scores